Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Clinical information of the enrolled patients with glioma^{^a}
6-Month Follow-Up Patients (n = 32) P Value
Treatment-Related Change (n = 20) Tumor Progression (n =12)
WHO grade .71
 Grade II 3 2 
 Grade III 6 2 
 Grade IV 11 8 
No. of male patients 12 (60%) 6 (50%) .59
Age (yr) 61.5 (36–70) 59.5 (21–69) .71
Surgical extent (%) .46
 Biopsy or partial resection 14 7 
 Gross total resection 6 5 
Postoperative standard radiation therapy or concurrent chemoradiation therapy 19 11 .55
↵a Data are expressed as the median and range for continuous variables. The χ² test was used to test for differences in categoric variables between the 6-month stable and tumor-progression groups.

6-Month Follow-Up	Patients (n = 32)		P Value
6-Month Follow-Up	Treatment-Related Change (n = 20)	Tumor Progression (n =12)	P Value
WHO grade			.71
Grade II	3	2
Grade III	6	2
Grade IV	11	8
No. of male patients	12 (60%)	6 (50%)	.59
Age (yr)	61.5 (36–70)	59.5 (21–69)	.71
Surgical extent (%)			.46
Biopsy or partial resection	14	7
Gross total resection	6	5
Postoperative standard radiation therapy or concurrent chemoradiation therapy	19	11	.55